3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
25
Gastrointestinal
4
Plasma cell
3
Thoracic
2
Other
2
Myeloid
2
Genitourinary
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Conditions
Leukemia, Myeloid, Acute
879
Leukemia, Lymphocytic, Chronic, B-Cell
560
Leukemia
426
Precursor Cell Lymphoblastic Leukemia-Lymphoma
331
Hematologic Neoplasms
331
Myelodysplastic Syndromes
302
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
244
Lymphoma, Non-Hodgkin
224
Recurrence
222
Lymphoma
196
Neoplasms
195
Multiple Myeloma
129
Lymphoma, Mantle-Cell
119
Lymphoma, Large B-Cell, Diffuse
114
Lymphoma, Follicular
114
Leukemia, Myelomonocytic, Chronic
89
Lymphoma, B-Cell
88
Lymphoma, B-Cell, Marginal Zone
85
Leukemia, B-Cell
79
Burkitt Lymphoma
64
Leukemia, Myeloid, Chronic-Phase
57
Waldenstrom Macroglobulinemia
56
Leukemia, Myeloid
53
Hodgkin Disease
47
Hematologic Diseases
47
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
45
Myeloproliferative Disorders
40
Primary Myelofibrosis
39
Bronchiolitis Obliterans Syndrome
35
Anemia, Refractory, with Excess of Blasts
32
Interventions
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Venous Thromboembolism
×
Other hematologic neoplasm
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled